MHC class I and integrin ligation induce ERK activation via an mTORC2-dependent pathway

Biochemical and Biophysical Research Communications

Volumn 369, Issue 2, 2008, Pages 781-787

  Jindra, Peter T ^a   Jin, Yi Ping ^a   Jacamo, Rodrigo ^b   Rozengurt, Enrique ^b   Reed, Elaine F ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Endothelial cells; ERK; HLA class I; MHC; mTORC2; Signal transduction; siRNA

Indexed keywords

INTEGRIN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAMMALIAN TARGET OF RAPAMYCIN; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 1 PROTEIN; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 2 PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; RAPAMYCIN; SMALL INTERFERING RNA; THREONINE; TYROSINE; UNCLASSIFIED DRUG;

ARTICLE; CELL SURFACE; CONTROLLED STUDY; ENDOTHELIUM CELL; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; SIGNAL TRANSDUCTION;

CELLS, CULTURED; ENDOTHELIAL CELLS; ENZYME ACTIVATION; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; HLA-A ANTIGENS; HUMANS; INTEGRINS; PROTEIN KINASES; SIGNAL TRANSDUCTION;

EID: 40849087786     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2008.02.093     Document Type: Article

References (34)

1. Jindra P.T., Jin Y.P., Rozengurt E., and Reed E.F. HLA class I antibody-mediated endothelial cell proliferation via the mTOR pathway. J. Immunol. 180 (2008) 2357-2366
2. Han S., Khuri F.R., and Roman J. Fibronectin stimulates non-small cell lung carcinoma cell growth through activation of Akt/mammalian target of rapamycin/S6 kinase and inactivation of LKB1/AMP-activated protein kinase signal pathways. Cancer Res. 66 (2006) 315-323
3. Sakakibara K., Liu B., Hollenbeck S., and Kent K.C. Rapamycin inhibits fibronectin-induced migration of the human arterial smooth muscle line (E47) through the mammalian target of rapamycin. Am. J. Physiol. Heart Circ. Physiol. 288 (2005) H2861-H2868
4. Kornberg L., Earp H.S., Parsons J.T., Schaller M., and Juliano R.L. Cell adhesion or integrin clustering increases phosphorylation of a focal adhesion-associated tyrosine kinase. J. Biol. Chem. 267 (1992) 23439-23442
5. Hara K., Maruki Y., Long X., Yoshino K., Oshiro N., Hidayat S., Tokunaga C., Avruch J., and Yonezawa K. Raptor, a binding partner of target of rapamycin (TOR), mediates TOR action. Cell 110 (2002) 177-189
6. Kim D.H., Sarbassov D.D., Ali S.M., King J.E., Latek R.R., Erdjument-Bromage H., Tempst P., and Sabatini D.M. mTOR interacts with raptor to form a nutrient-sensitive complex that signals to the cell growth machinery. Cell 110 (2002) 163-175
7. Nojima H., Tokunaga C., Eguchi S., Oshiro N., Hidayat S., Yoshino K., Hara K., Tanaka N., Avruch J., and Yonezawa K. The mammalian target of rapamycin (mTOR) partner, raptor, binds the mTOR substrates p70 S6 kinase and 4E-BP1 through their TOR signaling (TOS) motif. J. Biol. Chem. 278 (2003) 15461-15464
8. Yang Q., Inoki K., Ikenoue T., and Guan K.L. Identification of Sin1 as an essential TORC2 component required for complex formation and kinase activity. Genes Dev. 20 (2006) 2820-2832
9. Sarbassov D.D., Ali S.M., Kim D.H., Guertin D.A., Latek R.R., Erdjument-Bromage H., Tempst P., and Sabatini D.M. Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton. Curr. Biol. 14 (2004) 1296-1302
10. Pearce L.R., Huang X., Boudeau J., Pawlowski R., Wullschleger S., Deak M., Ibrahim A., Gourlay R., Magnuson M.A., and Alessi D.R. Identification of Protor as a novel Rictor-binding component of mTOR-complex-2. Biochem. J. 405 (2007) 513-522
11. Hernandez-Negrete I., Carretero-Ortega J., Rosenfeldt H., Hernandez-Garcia R., Calderon-Salinas J.V., Reyes-Cruz G., Gutkind J.S., and Vazquez-Prado J. P-Rex1 links mTOR signaling to Rac activation and cell migration. J. Biol. Chem. 282 (2007) 23708-23715
12. Woo S.Y., Kim D.H., Jun C.B., Kim Y.M., Haar E.V., Lee S.I., Hegg J.W., Bandhakavi S., and Griffin T.J. PRR5, a novel component of mTOR complex 2, regulates platelet-derived growth factor receptor beta expression and signaling. J. Biol. Chem. 282 (2007) 25604-25612
13. Sarbassov D.D., Guertin D.A., Ali S.M., and Sabatini D.M. Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science 307 (2005) 1098-1101
14. Jacinto E., Loewith R., Schmidt A., Lin S., Ruegg M.A., Hall A., and Hall M.N. Mammalian TOR complex 2 controls the actin cytoskeleton and is rapamycin insensitive. Nat. Cell Biol. 6 (2004) 1122-1128
15. Gangloff Y.G., Mueller M., Dann S.G., Svoboda P., Sticker M., Spetz J.F., Um S.H., Brown E.J., Cereghini S., Thomas G., and Kozma S.C. Disruption of the mouse mTOR gene leads to early postimplantation lethality and prohibits embryonic stem cell development. Mol. Cell. Biol. 24 (2004) 9508-9516
16. Murakami M., Ichisaka T., Maeda M., Oshiro N., Hara K., Edenhofer F., Kiyama H., Yonezawa K., and Yamanaka S. mTOR is essential for growth and proliferation in early mouse embryos and embryonic stem cells. Mol. Cell. Biol. 24 (2004) 6710-6718
17. Guertin D.A., Stevens D.M., Thoreen C.C., Burds A.A., Kalaany N.Y., Moffat J., Brown M., Fitzgerald K.J., and Sabatini D.M. Ablation in mice of the mTORC components raptor, rictor, or mLST8 reveals that mTORC2 is required for signaling to Akt-FOXO and PKCalpha, but not S6K1. Dev. Cell 11 (2006) 859-871
18. Shiota C., Woo J.T., Lindner J., Shelton K.D., and Magnuson M.A. Multiallelic disruption of the rictor gene in mice reveals that mTOR complex 2 is essential for fetal growth and viability. Dev. Cell 11 (2006) 583-589
19. Chang F., Steelman L.S., Lee J.T., Shelton J.G., Navolanic P.M., Blalock W.L., Franklin R.A., and McCubrey J.A. Signal transduction mediated by the Ras/Raf/MEK/ERK pathway from cytokine receptors to transcription factors: potential targeting for therapeutic intervention. Leukemia 17 (2003) 1263-1293
20. Yeh M., Leitinger N., de Martin R., Onai N., Matsushima K., Vora D.K., Berliner J.A., and Reddy S.T. Increased transcription of IL-8 in endothelial cells is differentially regulated by TNF-alpha and oxidized phospholipids. Arterioscler. Thromb. Vasc. Biol. 21 (2001) 1585-1591
21. Jiang X., Jacamo R., Zhukova E., Sinnett-Smith J., and Rozengurt E. RNA interference reveals a differential role of FAK and Pyk2 in cell migration, leading edge formation and increase in focal adhesions induced by LPA in intestinal epithelial cells. J. Cell. Physiol. 207 (2006) 816-828
22. Sarbassov D.D., Ali S.M., Sengupta S., Sheen J.H., Hsu P.P., Bagley A.F., Markhard A.L., and Sabatini D.M. Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB. Mol. Cell 22 (2006) 159-168
23. Petersen J., and Nurse P. TOR signalling regulates mitotic commitment through the stress MAP kinase pathway and the Polo and Cdc2 kinases. Nat. Cell Biol. 9 (2007) 1263-1272
24. Vomastek T., Iwanicki M.P., Schaeffer H.J., Tarcsafalvi A., Parsons J.T., and Weber M.J. RACK1 targets the ERK/MAP Kinase pathway to link integrin engagement with focal adhesion disassembly and cell motility. Mol. Cell. Biol. 27 (2007) 8296-8305
25. Sawhney R.S., Cookson M.M., Omar Y., Hauser J., and Brattain M.G. Integrin alpha2-mediated ERK and calpain activation play a critical role in cell adhesion and motility via focal adhesion kinase signaling: identification of a novel signaling pathway. J. Biol. Chem. 281 (2006) 8497-8510
26. Wilson S.H., Ljubimov A.V., Morla A.O., Caballero S., Shaw L.C., Spoerri P.E., Tarnuzzer R.W., and Grant M.B. Fibronectin fragments promote human retinal endothelial cell adhesion and proliferation and ERK activation through alpha5beta1 integrin and PI 3-kinase. Invest. Ophthalmol. Vis. Sci. 44 (2003) 1704-1715
27. Puente L.G., and Ostergaard H.L. Beta 1/beta 3 integrin ligation is uncoupled from ERK1/ERK2 activation in cytotoxic T lymphocytes. J. Leukoc. Biol. 73 (2003) 391-398
28. Jacinto E., Facchinetti V., Liu D., Soto N., Wei S., Jung S.Y., Huang Q., Qin J., and Su B. SIN1/MIP1 maintains rictor-mTOR complex integrity and regulates Akt phosphorylation and substrate specificity. Cell 127 (2006) 125-137
29. Reed E.F., Demetris A.J., Hammond E., Itescu S., Kobashigawa J.A., Reinsmoen N.L., Rodriguez E.R., Rose M., Stewart S., Suciu-Foca N., Zeevi A., and Fishbein M.C. Acute antibody-mediated rejection of cardiac transplants. J. Heart Lung Transplant. 25 (2006) 153-159
30. Terasaki P.I., and Cai J. Humoral theory of transplantation: further evidence. Curr. Opin. Immunol. 17 (2005) 541-545
31. Russell P.S., Chase C.M., and Colvin R.B. Alloantibody- and T cell-mediated immunity in the pathogenesis of transplant arteriosclerosis: lack of progression to sclerotic lesions in B cell-deficient mice. Transplantation 64 (1997) 1531-1536
32. Jindra P.T., Hsueh A., Hong L., Gjertson D.W., Shen X.-D., Gao F., Dang J., Mischel P.S., Baldwin III W.M., Fishbein M.C., Kupiec-Weglinski J.W., and Reed E.F. Anti-MHC class I antibody of proliferation and survival signaling in murine cardiac allografts. J. Immunol. 180 (2008) 2214-2224
33. Eisen H.J., Tuzcu E.M., Dorent R., Kobashigawa J., Mancini D., Valantine-von Kaeppler H.A., Starling R.C., Sorensen K., Hummel M., Lind J.M., Abeywickrama K.H., and Bernhardt P. Everolimus for the prevention of allograft rejection and vasculopathy in cardiac-transplant recipients. N. Engl. J. Med. 349 (2003) 847-858
34. Vigano M., Tuzcu M., Benza R., Boissonnat P., Haverich A., Hill J., Laufer G., Love R., Parameshwar J., Pulpon L.A., Renlund D., Abeywickrama K., Cretin N., Starling R.C., and Eisen H.J. Prevention of acute rejection and allograft vasculopathy by everolimus in cardiac transplants recipients: a 24-month analysis. J. Heart Lung Transplant. 26 (2007) 584-592